This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. Element AI Jumpstarts Canada’s AI Game Canada is capitalizing on the opportunity
This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. “Our view of success isn’t how many home runs we back, it’s
This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. Versant Ventures Goes Behind-the-Scenes on the Second Largest VC Deal in H1
This article is part of a new series, CVCA Quarterly Exclusive, written and published by the Canadian Venture Capital and Private Equity Association. This series provides an analysis of the CVCA’s most recently published VC & PE Canadian Market Overview through expert commentary and perspectives. Last year was undoubtedly a huge year for venture capital investment activity
Quark Venture’s Partner & CEO weighs in on the future of AI and its role in the healthcare vertical There’s been plenty of media coverage lately about artificial intelligence. Most reporting has been generated through the vastly different views of people like Elon Musk the CEO of Tesla, SpaceX, and Neuralink, and Mark Zuckerberg, the
Although not as flush as the first quarter last year, the Canadian venture capital industry is still looking strong. Based on final Q1 2017 CVCA data (Q2 2017 final data scheduled to be released on August 23rd), $905M was disbursed over 98 deals in the first quarter. This compares to $956M over 128 deals from
Photo Credit: Carey Diamond A month after announcing its intention to go public, Markham Ontario-based Real Matters Inc. (TSX: REAL) has begun trading, raising C$156 million with common shares at C$13.00 per share, giving the company a valuation in excess of C$1 billion. The Real Matters IPO marks an end to a two-year dry spell for
Vancouver-based Zymeworks (TSE/NYSE: ZYME) debuted on the public markets last Friday, just two weeks after announcing its intention to go public. The company raised CAD $79.7 million in the IPO from the sale of 4.5 million common shares at CAD $17 per share. Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and
Evaluating an investment involves complex research. According to early-stage micro seed investment fund and mentoring program, Seedcamp, determining the value of an investment consists of market forces of the industry and sector of the company, the balance between the demand and supply of money, the frequency and size of latest exits and a stack of other quantitative
The University of Toronto’s Impact Centre released the results of new research which is shining a light into the success of Canadian startups. According to the new research, many Canadian technology companies wait until their products are launched before spending funds on crucial functions such as marketing and sales. This practice is delaying growth and
